Skip to main content
Log in

Het gebruik van MRI-scan bij prostaatkanker

  • Published:
Bijblijven

Samenvatting

Magnetische resonantie imaging (MRI) is een vorm van radiologische beeldvorming waarbij geen röntgenstraling maar radiofrequente golven gebruikt worden om wekedelenweefsels in het lichaam af te beelden. Het gebied van het kleine bekken, waarin zich ook de prostaat bevindt, is hiervoor uitstekend geschikt. Er wordt steeds vaker een MRI-scan verricht bij patiënten met (een verdenking op) prostaatkanker. Om inzicht te krijgen in de mogelijkheden van MRI bij prostaatkanker, is het van belang eerst enige informatie te verschaffen over de anatomie van de prostaat en de pathologie van prostaatkanker, alsook over de overige diagnostische hulpmiddelen en mogelijke therapiekeuzes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figuur 1
Figuur 2
Figuur 3
Figuur 4
Figuur 5
Figuur 6
Figuur 7
Figuur 8
Figuur 9
Figuur 10
Figuur 11
Figuur 12
Figuur 13
Figuur 14
Figuur 15

Literatuur

  1. IKNL. Cijfers over kanker. http://www.cijfersoverkanker.nl/. Geraadpleegd op 29 maart 2016.

  2. McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT MR. 1988;9(5):329–34.

    CAS  PubMed  Google Scholar 

  3. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89(8):1800–9.

    Article  CAS  PubMed  Google Scholar 

  4. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Pt 2):1709–13.

    CAS  PubMed  Google Scholar 

  5. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906.

    Article  CAS  PubMed  Google Scholar 

  6. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273–9.

    Article  CAS  PubMed  Google Scholar 

  7. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89(6):538–42.

    Article  CAS  PubMed  Google Scholar 

  8. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol. 1990;14(3):240–7.

    Article  CAS  PubMed  Google Scholar 

  9. Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993;17(12):1252–61.

    Article  CAS  PubMed  Google Scholar 

  10. Saitoh H, Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer. 1990;65(8):1843–6.

    Article  CAS  PubMed  Google Scholar 

  11. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.

    Article  PubMed  Google Scholar 

  12. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M‑O, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011;60(2):291–303.

    Article  PubMed  Google Scholar 

  13. Velonas VM, Woo HH, Remedios CG dos, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034–60.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980;40(12):4658–62.

    CAS  PubMed  Google Scholar 

  15. Ellis WJ, Brawer MK. The significance of isoechoic prostatic carcinoma. J Urol. 1994;152(6 Pt 2):2304–7.

    CAS  PubMed  Google Scholar 

  16. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165(5):1554–9.

    Article  CAS  PubMed  Google Scholar 

  17. Scherr DS, Eastham J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002;20(1):18–31.

    Article  PubMed  Google Scholar 

  18. King CR, McNeal JE, Gill H, Presti JC. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004;59(2):386–91.

    Article  PubMed  Google Scholar 

  19. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477–94.

    Article  PubMed  Google Scholar 

  20. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, et al. Prostate cancer: local staging at 3‑T endorectal MR imaging – early experience. Radiology. 2006;238(1):184–91.

    Article  PubMed  Google Scholar 

  21. Heijmink SWTPJ, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TWJ, Huisman HJ, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T – comparison of image quality, localization, and staging performance. Radiology. 2007;244(1):184–95.

    Article  PubMed  Google Scholar 

  22. Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95.

    Article  PubMed  Google Scholar 

  23. Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology. 2012;263(3):751–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Vargas HA, Lawrence EM, Mazaheri Y, Sala E. Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World J Radiol. 2015;7(8):184–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hambrock T, Somford DM, Huisman HJ, Oort IM van, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453–61.

    Article  PubMed  Google Scholar 

  26. Hötker AM, Mazaheri Y, Aras Ö, Zheng J, Moskowitz CS, Gondo T, et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 2016;206(4):756–63.

    Article  PubMed  Google Scholar 

  27. Hoeks CMA, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SWTPJ, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46–66.

    Article  PubMed  Google Scholar 

  28. Vos EK, Kobus T, Litjens GJS, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz JO, et al. Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol. 2015;50(8):490–7.

    Article  CAS  PubMed  Google Scholar 

  29. Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–53.

    Article  PubMed  Google Scholar 

  30. Thompson JE, Leeuwen PJ van, Moses D, Shnier R, Brenner P, Delprado W, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol. 2016;195(5):1428–35.

    Article  CAS  PubMed  Google Scholar 

  31. Hoeks CMA, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3‑T multiparametric MR imaging. Radiology. 2013;266(1):207–17.

    Article  PubMed  Google Scholar 

  32. Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, et al. Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiother Oncol. 2015;115(2):186–90.

    Article  PubMed  Google Scholar 

  33. Dinh CV, Steenbergen P, Ghobadi G, Heijmink SWTJP, Pos FJ, Haustermans K, et al. Magnetic resonance imaging for prostate cancer radiotherapy. Phys Med. 2016;32(3):446–51.

    Article  PubMed  Google Scholar 

  34. Scheenen TWJ, Heijmink SWTPJ, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245(2):507–16.

    Article  PubMed  Google Scholar 

  35. Pondman KM, Fütterer JJ, Haken B ten, Schultze Kool LJ, Witjes JA, Hambrock T, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008;54(3):517–27.

    Article  PubMed  Google Scholar 

  36. ACR, PI-RADS v2. 2015 http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADS%20V2.pdf.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stijn Heijmink.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heijmink, S. Het gebruik van MRI-scan bij prostaatkanker. Bijblijven 32, 234–251 (2016). https://doi.org/10.1007/s12414-016-0136-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12414-016-0136-3

Navigation